脂蛋白精细化亚组分检测及临床应用:现状与前景

Refined lipoprotein subfraction detection and clinical application:current status and prospects

摘要:

血脂异常是动脉粥样硬化性心血管疾病重要的危险因素。目前临床上以常规血脂检测项目为指导的干预策略在降低其发病风险方面仍存在明显不足。脂蛋白亚组分中蕴藏着挖掘残余风险的巨大潜力,因此亟待解决以下问题:①如何应用脂蛋白及亚组分检测,识别并控制与血脂相关的“残余风险”；②如何围绕脂蛋白精细表型展开研究,揭示其在动脉粥样硬化性心血管疾病风险预测中的作用,发现新的风险标志物,并探寻降脂与抗动脉粥样硬化的新靶点；③如何推动脂蛋白及亚组分检测尽快进入临床应用,进一步提升动脉粥样硬化性心血管疾病的预防、诊断和治疗水平。针对关键问题进行精准突破和攻关,将有效提升我国在脂蛋白代谢异常及动脉粥样硬化性心血管疾病的临床防治和研究整体水平,进而降低发病风险和减轻疾病负担。

Abstract:

Dyslipidemia represents a crucial risk factor for atherosclerotic cardiovascular diseases (ASCVD). Currently, intervention strategies guided by routine blood lipid testing in clinical practice still have notable limitations in reducing its incidence risk. Lipoprotein subfractions hold great potential for uncovering residual risks, highlighting the urgent need to address the following key questions:①How to utilize lipoprotein and subfraction testing to identify and control lipid-related residual risks; ②How to carry out research centered on fine lipoprotein phenotypes to uncover their role in predicting ASCVD risk, discover new risk markers, and identify novel targets for lipid-lowering and anti-atherosclerotic treatment; ③How to facilitate the prompt clinical implementation of lipoprotein and subfraction testing to further improve the prevention, diagnosis, and treatment of ASCVD. Targeted breakthroughs in these issues will contribute to comprehensively improving the clinical prevention, treatment, and research levels of lipoprotein metabolism disorders and ASCVD in China, thereby reducing the incidence risk and disease burden.